Press Releases

Abbott announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor (ETAR) antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney...

Reata Pharmaceuticals and Abbott announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other...

Novartis presented today a strategic overview of the company's diversified healthcare portfolio which creates the potential for future sustainable growth. The company's focused healthcare portfolio across key growth segments in healthcare provides Novartis a leading position in the respective...

Pfizer Inc. announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers.  The University of...

Pfizer Inc. announced results from the EMPHASIS-HF trial(1) showing a statistically significant reduction in risk of cardiovascular (CV) death or heart failure (HF) hospitalization for patients with chronic heart failure with mild symptoms treated with Inspra® (eplerenone) versus those...

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic(R) (nebivolol) and Savella(R) (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively,...

  Endo Pharmaceuticals announced that the U.S. FDA has informed the company that FDA no longer sees a need to convene a joint meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk...